3 completed, 1 active not recruiting, 1 unknown. 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Granulosa cell tumor of the ovary: new trials by email Literature Review of Granulosa cell tumor of the ovary trials Research Report on Granulosa cell tumor of the ovary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors Biospecimen Collection, Chest Radiography, Computed Tomography - Adult Ovarian Granulosa Cell Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-08 | 2026-07-28 |
| Nirogacestat in Ovarian Granulosa Cell Tumors Nirogacestat - Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor | Phase 2 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 53 | 2022-08-30 | 2026-08-25 |
| Luspatercept in Metastatic AGCT of the Ovary Luspatercept - Adult Granulosa Cell Tumor of the Ovary | Not applicable | Completed | University Health Network, Toronto | 1 | 2022-05-30 | 2024-02-12 |
| Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Bleomycin Sulfate, Carboplatin, Cisplatin - Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma | Phase 2 | Unknown | GOG Foundation | 63 | 2010-02-08 | 2022-01-25 |
| Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Bevacizumab, Laboratory Biomarker Analysis - Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2008-09-22 | 2019-07-23 |
Ovarian gynandroblastoma (2) · Sertoli-Leydig Cell Tumor (2) · Ovarian Neoplasms (1)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Ovarian Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Genital Diseases, Male (2)
1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Bleomycin (1) · Carboplatin (1) · Cisplatin (1) · Disulfides (1) · Immunoglobulin G (1) · Leuprolide (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Platinum (1) · Specimen Handling (1) · Taxes (1) · X-Rays (1) · darolutamide (1)
National Cancer Institute (NCI) (2) · GOG Foundation (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · University Health Network, Toronto (1)
United States (4) · Canada (2) · Poland (1)
Jubilee Brown (2) · Amit Oza, M.D. (1) · Elizabeth Hopp (1)
PMID 39265466, PMID 41518037, PMID 42070324, PMID 42574969
U10CA180868 (3), U10CA027469 (2)